CVR number 31375509
Industry 46.4620 Wholesale of pharmaceutical goods

FERDINAND MEDICAL ApS

 

Quicksearch
from your own companies
Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...
Bankruptcy Risk 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Bankruptcy risk for industry  1.1% 1.1% 1.1% 1.1% 1.1%  
Bankruptcy risk  0.9% 1.1% 1.3% 1.0% 1.4%  
Credit score (0-100)  90 84 78 86 76  
Credit rating  A BBB BBB A BBB  
Credit limit (kDKK)  260.1 144.4 47.2 269.2 34.3  
How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Net sales  0 0 0 0 0  
Gross profit  2,857 3,886 4,452 4,516 4,936  
EBITDA  559 787 732 908 547  
EBIT  559 787 732 908 547  
Pre-tax profit (PTP)  557.6 782.3 721.7 901.6 550.3  
Net earnings  428.2 603.6 551.3 676.8 414.7  
Pre-tax profit without non-rec. items  558 782 722 902 550  
 
See the entire income statement

Balance sheet (kDKK) 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  2,592 2,696 3,047 3,724 4,139  
Interest-bearing liabilities  27.4 29.4 0.0 0.0 0.0  
Balance sheet total (assets)  4,244 4,825 7,189 6,713 7,675  
Net Debt  -442 -38.7 -176 -138 -1,681  
 
See the entire balance sheet

Volume 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  2,857 3,886 4,452 4,516 4,936  
Gross profit growth  22.2% 36.0% 14.6% 1.5% 9.3%  
Employees  4 4 4 5 5  
Employee growth %  0.0% 0.0% 0.0% 25.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  4,244 4,825 7,189 6,713 7,675  
Balance sheet change%  4.2% 13.7% 49.0% -6.6% 14.3%  
Added value  558.9 787.4 731.9 908.2 547.3  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 0 0 0 0  
Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  4.0 5.0 5.0 5.0 5.0  

Profitability 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  19.6% 20.3% 16.4% 20.1% 11.1%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  13.5% 17.4% 12.2% 13.1% 7.7%  
ROI %  23.4% 29.5% 25.4% 26.8% 14.1%  
ROE %  18.0% 22.8% 19.2% 20.0% 10.5%  

Solidity 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Equity ratio %  61.1% 55.9% 42.4% 55.5% 53.9%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  -79.0% -4.9% -24.0% -15.2% -307.1%  
Gearing %  1.1% 1.1% 0.0% 0.0% 0.0%  
Net interest  0 0 0 0 0  
Financing costs %  15.5% 21.6% 70.8% 0.0% 0.0%  

Liquidity 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Quick Ratio  0.6 0.5 0.6 0.7 1.1  
Current Ratio  2.6 2.3 1.7 2.2 2.2  
Cash and cash equivalent  469.1 68.0 175.8 138.1 1,680.8  

Capital use efficiency 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  2,594.1 2,710.6 2,987.1 3,663.9 4,078.6  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Net sales / employee  0 0 0 0 0  
Added value / employee  140 197 183 182 109  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  140 197 183 182 109  
EBIT / employee  140 197 183 182 109  
Net earnings / employee  107 151 138 135 83